Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diagnostics compliance issues reduce Abbott's margins

This article was originally published in Clinica

Executive Summary

The ongoing struggle at Abbott Diagnostics to bring US production facilities up to GMP standard led to a reduction in Abbott Laboratories' gross margin ratio in the first quarter of 2003. The compliance issues were also behind a 10% drop in US diagnostics sales to $270m, although this had been expected. Another reason for the declining sales was the discontinuation of two low-margin infection tests at the end of last year (see Clinica No 1042, p 11).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061853

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel